Comparison of Treatment Modalities for Locally Advanced Gastric Cancer: A Propensity Score Matching Analysis

Jianglong Han, Zhihua Nie, Ping Li, Hongwei Shi, Shijie Wang, Qin Li, Rui Zhang, Yunfeng Qiao, Kejie Huang, Zhenming FuJournal of Cancer 2020 · DOI

Abstract

Background: Optimum treatment strategies for locally advanced gastric cancer (LAGC) remain a subject of debate. This study evaluates the efficacy of various treatment modalities, focusing on the extent of lymph node dissection and adjuvant therapy.

Methods: A retrospective cohort of 350 patients was analyzed alongside a validation cohort of 3,568 patients from the SEER database. Patients were categorized into four groups: D1 dissection plus chemotherapy (D1CT), D1 plus chemoradiotherapy (D1CRT), D2 plus chemotherapy (D2CT), and D2 plus chemoradiotherapy (D2CRT). Propensity score matching (PSM) was employed to adjust for baseline confounding.

Results: D2CRT demonstrated superior overall survival (OS) and disease-free survival (DFS) compared to other groups. Notably, D1CRT achieved survival outcomes comparable to D2CT.

Conclusions: D2CRT is the most effective modality for LAGC. For patients receiving D1 dissection, adjuvant chemoradiotherapy serves as a viable salvage option.

Introduction

Locally advanced gastric cancer (LAGC) is a significant global health challenge. While surgical resection is the cornerstone of treatment, the optimal combination of lymph node dissection (D1 vs. D2) and adjuvant therapy (chemotherapy vs. chemoradiotherapy) is not universally agreed upon. D2 dissection is technically demanding, and in many real-world clinical settings, D1 dissection is more common. This study investigates whether adjuvant chemoradiotherapy can compensate for less extensive surgical dissection.

Methods

The study utilized a primary cohort of 350 patients from Wuhan University and a validation cohort of 3,568 patients from the SEER database. To mitigate selection bias inherent in retrospective data, Propensity Score Matching (PSM) was used to balance baseline characteristics such as age, gender, and tumor stage across the four treatment groups (D1CT, D1CRT, D2CT, D2CRT).

Standardized differences of baseline characteristics before and after propensity score matching.

Key Results

The analysis revealed that D2 dissection combined with adjuvant chemoradiotherapy (D2CRT) yielded the best clinical outcomes. In the primary cohort after PSM, the D2CRT group achieved a mean OS of 110.7 months and a mean DFS of 95.2 months, significantly outperforming the other three modalities.

Crucially, the study found that adding radiotherapy to D1 dissection (D1CRT) resulted in survival rates similar to those of D2 dissection with chemotherapy alone (D2CT). In the validation cohort, these trends were confirmed, showing a clear survival hierarchy where D2CRT remains the superior choice.

Cancer-specific survival (CSS) curves for the four treatment modalities in the validation cohort.

Discussion and Conclusion

The findings suggest that D2CRT should be considered the gold standard for LAGC treatment when feasible. However, in clinical scenarios where a D2 dissection cannot be performed, adjuvant chemoradiotherapy (D1CRT) provides a critical "salvage" effect, elevating patient outcomes to levels comparable with D2CT. This offers a practical strategy for clinicians in resource-limited settings or for patients who are not candidates for extensive surgery. Future prospective trials are needed to further validate these findings and refine treatment protocols.

Summary updated

Abstract

<b>Background</b>: A consensus regarding optimum treatment strategies for locally advanced gastric cancer (LAGC) has not yet been reached. We aimed to evaluate the efficacy of various treatment modalities for LAGC and provided clinicians salvage options under real-world situation. <b>Methods</b>: Medical charts of patients with LAGC who underwent radical resection plus adjuvant chemotherapy or chemoradiotherapy from July 2003 to December 2014 were included. Validation cohort were selected from SEER database between 2004 and 2014. Kaplan-Meier and Cox proportional hazardous models were used to evaluate the overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Propensity score matching (PSM) was used to adjust for potential baseline confounding. <b>Results</b>: A total of 350 patients were included and divided into D1 dissection plus chemotherapy group (D1CT, n = 74), D1 dissection plus adjuvant chemoradiotherapy group (D1CRT, n = 69), D2 dissection plus adjuvant chemotherapy group (D2CT, n = 134), and D2 dissection plus adjuvant chemoradiotherapy group (D2CRT, n = 73). PSM identified 50 patients in each group. After PSM, better DFS (<i>P</i> for D2CRT vs. D1CT, D1CRT, and D2CT was 0.001, 0.006, and 0.001, respectively) and OS (<i>P</i> for D2CRT vs. D1CT, D1CRT, and D2CT was 0.001, 0.011, and 0.022, respectively) were found for the D2CRT group (mean, OS = 110.7months, DFS = 95.2 months) than the other groups. Similar findings were further validated in the Surveillance, Epidemiology, and End Results database (SEER) cohort. In addition, patients in the D1CRT group achieved similar survival outcomes to those in the D2CT group (mean OS, 72.8 vs. 59.1 months, <i>P</i> = 0.86; mean DFS, 54.4 vs. 34.1 months, <i>P</i> = 0.460). <b>Conclusions</b>: The results of the study indicated the better role for D2CRT in treating the LAGC, meanwhile, the patients treated with D1CRT might achieve similar survival as that of D2CT patients.
BibTeX
@article{han2020comparison,
  author = {Jianglong Han and Zhihua Nie and Ping Li and Hongwei Shi and Shijie Wang and Qin Li and Rui Zhang and Yunfeng Qiao and Kejie Huang and Zhenming Fu},
  title = {{Comparison of Treatment Modalities for Locally Advanced Gastric Cancer: A Propensity Score Matching Analysis}},
  journal = {Journal of Cancer},
  year = {2020},
  doi = {10.7150/jca.41082},
}
Figure